Prospective Randomized Controlled Trial Comparing Adjuvant Concomitant Chemotherapy and Radiotherapy Versus Radiotherapy Alone in High Intermediate and High Risk Endometrial Carcinoma Patients / (Record no. 172218)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06026namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250529123618.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250520s2024 ua a|||fr|m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99466 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.99466 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.19.06.Ph.D.2024.Re.P. |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Reem Soudy Elewa Mohamed Younes, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Prospective Randomized Controlled Trial Comparing Adjuvant Concomitant Chemotherapy and Radiotherapy Versus Radiotherapy Alone in High Intermediate and High Risk Endometrial Carcinoma Patients / |
| Statement of responsibility, etc. | By Reem Soudy Elewa Mohamed Younes; Under Supervision of Prof. Mervet Hassan El Naggar, Prof. Mohamed Mahmoud, Ass. Prof. Mohammed Ghareeb, Prof. Iman Attia Abedelgawad |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | دراسة اكلينيكية مستقبليه للمقارنة مابین نتائج العلاج الاشعاعي والكيماوي معا او العلاج الاشعاعي فقط في حالات سرطان الرحم عالي الخطورة / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 96 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 80-96. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Fifteen to twenty percent of the patients present with high-risk factors and they experience higher rates of recurrence and distant relapse. Several trials were conducted to find the optimum treatment for these group of patients in order to improve their prognosis.<br/>Patients and methods<br/>Phase II prospective randomized trial with 2 arms :<br/>•Arm A: Patients received adjuvant Radiotherapy only.<br/>•Arm B:Patients received concurrently with radiation weekly cisplatin 30-40 mg/m2 administered intravenously followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2 administrated intravenously at 21-day intervals <br/>Results:<br/>•Groups were comparable in terms of demographic factors. <br/>•All patients received their adjuvant radiotherapy with comparable rates of cystitis and proctitis between groups <br/>•Patient in group B suffered more hematologic toxicity then group A during radiation. . <br/>•78% of patients in group B received the full course of their adjuvant chemotherapy. <br/>•Patients in group B suffered from hematologic toxicities with rates higher than similar western trials.<br/>•25% of patients who received chemotherapy had grade II neuropathy and 14% had grade III. <br/>•PS at last follow up was worse in group B. <br/>•More patients in group A developed distant relapse while more patients in group B died of other causes. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | الخلفية العلمية و الهدف من الرساله:<br/>(15-20 %)من النساء يتم تشخيصهن بسرطان الرحم عالي الخطورة وتكون نتائج العلاج غير مرضية.<br/> مقارنة نتائج العلاج الاشعاعي والكيماوي معا ضد العلاج الاشعاعي فقط وذلك في حالات اورام الرحم عالي الخطورة.<br/>طرق البحث :<br/>أجريت هذه التجربة السريرية احادية الاخفاء العشوائية المقارنة على 83 امرأة مصابة بسرطان الرحم يخضعن لعملية استئصال جذري للرحم. تم اختيار المرضى بشكل عشوائي إلى مجموعتين للمقارنة بين العلاج الاشعاعي فقط ضد العلاج الاشعاعي والكيماوي:<br/>المجموعة الأولى: تلقت علاج اشعاعي . <br/>المجموعة الثانية: تلقت علاج اشعاعي وكيماوي<br/>النتائج:<br/>•كانت خصائص المرضى وخصائص الورم متشابهة الي حد كبير بين المجموعتين.<br/>•كانت خطط العلاج الاشعاعي متقاربه بين المجموعتين الي حد كبير<br/>•انهي جميع المرضي في المجموعتين العلاج الاشعاعي<br/>•لم يكن هناك اختلاف في نسب الاعراض الجانبية الحاده علي المثانة والمستقيم التي نتجت من العلاج الاشعاعي بين المجموعتين .<br/>•المرضي اللذين تلقوا علاج كيماوي مصاحب عانوا اكتر من تدهور صورة الدم<br/>•تمكن 78% من المرضي في المجموعة الثانية من اتمام العلاج الكيماوي المقرر لهم<br/>•كانت النسب التي تشير الي تثبيط النخاع الشوكي الناتج من العلاج الكيماوي اعلي من النسب العالمية<br/>•عاني 25%من المرضي في المجوعة الثانية من التهاب الأعصاب من الدرجة الثانية و 14% عانوا من الالتهاب من الدرجة الثالثة <br/>•كانت الحالة الصحية العامة عند اخر متابعة اسوأ للمرضي في المجوعة الثانية<br/>•كان نسب انتشار المرض اعلي في المجموعة الاولي ولكن عدد الوفيات أعلي في المجموعة الثانية. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issued also as CD |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Uterine cancer |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Radiotherapy |
| -- | Chemotherapy |
| -- | Uertine carcinoma |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mervet Hassan El Naggar |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Mahmoud |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohammed Ghareeb |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Iman Attia Abedelgawad |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Mervet Hassan El Naggar |
| -- | Mohamed Mahmoud |
| -- | Mohammed Ghareeb |
| -- | Iman Attia Abedelgawad |
| Universities | Cairo University |
| Faculties | Faculty of National Cancer Institute |
| Department | Department of Radiation Oncology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Nourhan |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 20.05.2025 | 91121 | Cai01.19.06.Ph.D.2024.Re.P. | 01010110091121000 | 20.05.2025 | 20.05.2025 | Thesis |